CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This research study is being done to find out if the immunotherapy drugs called CDX-301 and
CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal
doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with
metastatic triple negative breast cancer, and to determine a safe dose and treatment schedule
of the three drugs. This research study will also test how these treatments improve your
body's immune response against the cancer.